Fig. 5From: Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysisSubgroup analysis based on different IHC antibodies. a Stratified by the IHC antibodies of PD-L1 with progression-free survival and b stratified by the IHC antibodies of PD-L1 expression with overall survival. IHC, immunohistochemistry; CI, confidence interval; HR, hazard ratioBack to article page